Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
Concomitant H-WBI Yields Non-Inferior IBR, Shorter Treatment Time Vs Sequential WBI in High-Risk Early Breast CancerOctober 30th 2022
Supplemental radiation doses delivered concomitantly with hypofractionated whole breast irradiation in 15 fractions demonstrated non-inferior ipsilateral breast recurrence and similar toxicity compared with sequential boosts following whole breast irradiation in high-risk early-stage breast cancer.
ER Antagonist OP-1250 Demonstrates Continued Anti-Tumor Activity in Advanced ER+ HER2– Breast CancerOctober 29th 2022
Among patients with advanced and/or metastatic hormone receptor–positive HER-2 negative breast cancer, complete estrogen receptor antagonist OP-1250 continued to yield clinical benefits such as reductions in target tumor lesions.
Rogaratinib Demonstrates Comparable Efficacy and Safety Vs Chemotherapy in FGFR+ Advanced Urothelial CarcinomaOctober 27th 2022
Rogaratinib showed similar efficacy and manageable safety compared with chemotherapy in the management of FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma.
Sorafenib Plus SBRT Yields Improved Survival Vs Sorafenib Alone in Locally Advanced HCCOctober 25th 2022
Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.
Cabazitaxel at Lowered Dose, Increased Frequency Reduces Neutropenic Complications in Older Patients With mCRPCOctober 25th 2022
Based on findings from the phase 3 CABASTY trial, a fixed 16 mg/m2 dose of cabazitaxel every 2 weeks vs 25 mg/m2 every 3 weeks reduced neutropenic complications in elderly patients with mCRPC.
Conventional Radiotherapy and 5 Fraction SBRT Produce Comparable Toxicity in Prostate CancerOctober 24th 2022
According to findings from the phase 3 PACE-B trial, genitourinary and gastrointestinal toxicities were similar among patients with prostate cancer receiving conventionally fractioned or moderately hypofractionated radiotherapy and stereotactic body radiotherapy.
European Commission Grants Approval to Second-Line Axicabtagene Ciloleucel for R/R DLBCL/HGBLOctober 22nd 2022
The European Commission based its approval of axicabtagene ciloleucel as a second-line therapy for patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma on the efficacy findings of the phase 3 ZUMA-7 trial.
Pembrolizumab Plus Chemotherapy Demonstrates Continued Benefit in Recurrent/Metastatic HNSCCOctober 21st 2022
Findings from the phase 3 KEYNOTE-048 study indicated that long-lasting improved survival benefit can be achieved with pembrolizumab plus chemotherapy compared with cetuximab and chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Adjuvant Nivolumab Demonstrates Reduced Risk of Death or Recurrence Vs Placebo in Stage IIB/C MelanomaOctober 21st 2022
Patients with completely resected stage IIB/C melanoma experienced significant and clinically meaningful improvements in recurrence-free survival following treatment with adjuvant nivolumab compared with placebo.
Switch of Endocrine Therapy Backbone Yields PFS Benefit in ER+ HER2– Breast Cancer After ESR1 Mutation Onset, Before ProgressionOctober 21st 2022
Switch treatment with palbociclib and fulvestrant from aromatase inhibitors plus palbociclib upon onset of ESR1 blood mutations and before progression yielded better progression-free survival among those with estrogen receptor–positive, HER2-negative advanced breast cancer.
177Lu-FAP-2286 Yields Promising Preliminary Anti-Tumor Activity in Advanced/Metastatic Solid MalignanciesOctober 20th 2022
Data from the phase 1 LuMIERE study highlighted that targeted radiotherapy agent 177Lu-FAP-2286 demonstrated a manageable safety profile and promising preliminary antitumor activity.
FDA Grants Orphan Drug Designation to ET140203 T Cells for HepatoblastomaOctober 19th 2022
The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.
TissueCypher Barrett’s Esophagus Test Increases Risk Assessment Accuracy in High-Grade Dysplasia/Esophageal AdenocarcinomaOctober 18th 2022
Results from a randomized controlled trial highlighted that the TissueCypher Barrett’s Esophagus Test heightened accuracy for assessing progression risk in high-grade dysplasia and esophageal adenocarcinoma among patients with Barrett’s esophagus.
Deborah Axelrod, MD, Discusses the Developments in the World of Breast Cancer SurgeryOctober 18th 2022
As part of Breast Cancer Awareness Month, CancerNetwork® spoke with Deborah M. Axelrod, MD, about developments within the surgical breast cancer space, including decreasing the need for re-excision and full lymph node dissection.
Zanubrutinib Produces Improved Survival Compared with Ibrutinib in Final PFS Analysis for Relapsed/Refractory CLLOctober 17th 2022
Topline results from the phase 3 ALPINE trial’s final progression-free survival analysis highlighted that zanubrutinib yielded higher progression-free survival compared with ibrutinib in patients with chronic lymphocytic leukemia.
VBT Yields Less Urethra Radiation Exposure in Endometrial Cancer vs EBRT in CRCOctober 12th 2022
Results from a retrospective cohort study indicated that vaginal brachytherapy yielded less radiation exposure to the female urethra in patients with endometrial cancer than external beam radiation therapy for those with colorectal cancer.
Trifluridine/Tipiracil Plus Bevacizumab Reaches Survival Endpoint in mCRCOctober 11th 2022
Data from the phase 3 SUNLIGHT study highlighted the increased survival benefit of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil alone for the treatment of metastatic colorectal cancer.
Pembrolizumab Plus Lenvatinib May Serve as Potential Frontline Treatment for Non–Clear Cell RCCOctober 5th 2022
Patients with locally advanced/metastatic non–clear cell renal cell carcinoma experienced promising preliminary antitumor activity following treatment with pembrolizumab and lenvatinib in the first line.
Talazoparib and Enzalutamide Combo Yields Meaningful rPFS Improvement in mCRPC Regardless of HRR StatusOctober 5th 2022
The phase 3 TALAPRO-2 study met the primary end point of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations following treatment with a combination of talazoparib and enzalutamide.
Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and MoreOctober 2nd 2022
Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.
First-Line Maintenance Rucaparib Achieves Longer PFS Vs Placebo Across Subgroups in Newly Diagnosed Ovarian CancerSeptember 30th 2022
Results from the phase 3 ATHENA-MONO study suggest that rucaparib could serve as a promising first-line maintenance treatment option in newly diagnosed ovarian cancer.
Durvalumab Plus CRT Fails to Meet PFS End Point in High-Risk Locally Advanced Cervical CancerSeptember 30th 2022
Results from the phase 3 CALLA trial indicated that durvalumab in combination with chemoradiotherapy did not yield a meaningful improvement in progression-free survival compared with chemoradiotherapy alone in high-risk locally advanced cervical cancer.
Sacituzumab Govitecan Improved Outcomes in HR+/HER2– Metastatic Breast Cancer Vs Physician’s ChoiceSeptember 27th 2022
Results from a post-hoc subgroup analysis of the phase 3 TROPiCS-02 study indicated that sacituzumab govitecan improved efficacy outcomes vs physician’s choice of treatment in HER2-low and HER2 immunohistochemistry 0, hormone receptor–positive metastatic breast cancer.
European Commission Approves Nivolumab/Relatlimab Combo for Treatment of Unresectable or Metastatic MelanomaSeptember 25th 2022
The European Commission based its approval of nivolumab/relatlimab for patients with a PD-L1 expression of less than 1% on the results of the phase 2/3 RELATIVITY-047 trial.
Joel W. Neal, MD, PhD Highlights Promise of Cabozantinib ± Atezolizumab in Advanced NSCLC, But Cites Need for More ResearchSeptember 22nd 2022
Findings from the phase 3 COSMIC-021 trial, comparing the effect of cabozantinib alone or in combination with atezolizumab vs docetaxel for advanced non–small cell lung cancer previously treated with immunotherapy, though promising, highlighted further need for randomized data to confirm the regimen’s benefit in the second-line setting, according to Joel W. Neal, MD, PhD.